How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

731 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

83. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

lifestyle goals, including normal weight, were met. 279 The Sibutramine Cardiovascular Outcomes (SCOUT) trial followed up 10 000 patients with CVD or type 2 diabetes mellitus and found that even modest weight loss reduced cardiovascular mortality in the following 4 to 5 years. 280 Reduction in body weight improves control of hypertension. A meta-analysis of 25 trials showed mean SBP and DBP reductions of 4.4 and 3.6 mm Hg, respectively, with a 5.1-kg weight loss. 281 The US Preventive Services Task

2014 American Heart Association

85. Observational study: Metformin associated with better cardiovascular outcomes than other glycaemic therapies

glycaemic therapies Zachary T Bloomgarden Statistics from Altmetric.com Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined (...) cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interventions: no pharmacological glycaemic treatment, metformin monotherapy, insulin monotherapy, sulfonylurea monotherapy, metformin plus sulfonylurea and metformin plus insulin. Each group consisted of approximately 1000–1500 participants, randomised to either sibutramine or control (the main purpose of the trial

2014 Evidence-Based Medicine (Requires free registration)

86. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue (PubMed)

, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity

Full Text available with Trip Pro

2018 International journal of endocrinology

87. Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)

, carbamazepine, rifampicin, ketoconazole, fluconazole, itraconazole, voriconanzole, diltiazem, verapamil, dexamethasone, prednisolone, phenytoin, ritonavir, indinavir, nelfinavir, bosentan, telithromycin, nefazodone, St John's wort, orlistat, sibutramine and other strong CYP 3A4 inhibitors/ inducers Pregnant ladies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

88. Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone (PubMed)

key amino acid residues in the active site of CYP2B6, 2C19, 2E1, and 3A4. When sibutramine, clopidogrel, or chlorzoxazone was co-administered with sauchinone to mice, the systemic exposure of each drug was increased compared to that without sauchinone, because sauchinone reduced the metabolic clearance of each drug. In conclusion, when sauchinone was co-treated with drugs metabolized via CYP2B6, 2C19, 2E1, or 3A4, sauchinone-drug interactions occurred because sauchinone inhibited the CYP-mediated

Full Text available with Trip Pro

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

89. Idebenone Treatment of Early Parkinson's Diseasesymptoms

) Exclusion Criteria: (1)Patients with disturbance of consciousness, aphasia and mental illness; patients with major depression (HAD scale score ≥ 15 points) (2)Patients with Parkinson's superimposition syndrome and patients with secondary Parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.) (3)Patients who have long-term use of dopamine blockers (such as potent neuroleptics, sibutramine, reserpine, metoclopramide, etc

2018 Clinical Trials

90. Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

(phentermine, sibutramine, orlistat) or lipid dissolving injections within 3 months. Over 3 days of treatment with oral or parenteral corticosteroids within 2 weeks of the screening visit. Recent history (within 2 years prior to the screening visit) of alcohol or drug abuse. Significant change in smoking habits within 3 months prior to screening. Participated in any clinical study with an investigational drug, biologic, or device within 3 month prior to screening. Significant change in diet or level

2018 Clinical Trials

91. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials

that anti-obesity therapy was associated with weight loss regardless of the drug used. Orlistat and rimonabant may be associated with cardiovascular risk factor improvements, but sibutramine may contribute to increased incidence of cardiovascular events. Given the unknown risk for publication bias, missing detail on placebo treatments and limited quality assessment, these conclusions should be interpreted cautiously. Authors' objectives To assess the effects of anti-obesity drugs on cardiovascular risk (...) . Sibutramine (5mg to 15mg daily) and rimonabant (5mg to 20mg daily) were also investigated. Details of placebo treatments were not reported. Two reviewers independently selected studies for inclusion with disagreements being discussed with a third reviewer until consensus was reached. Assessment of study quality Two reviewers independently used the Jadad scale to assess trial quality based on randomisation, allocation concealment, blinding, completeness of follow-up, and use of intention-to-treat analysis

Full Text available with Trip Pro

2012 DARE.

92. Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta-analysis

pharmacotherapy for comparisons of ethnic groups. The data appeared to show positive weight management results with orlistat and sibutramine; weight loss with sibutramine was significantly lower in ethnic minorities versus Caucasians. The review was generally well conducted. The authors’ conclusions were suitably cautious and appear appropriate. Authors' objectives To compare the effectiveness of anti-obesity medications in ethnic minorities and white Caucasians. Searching MEDLINE, EMBASE, The Cochrane (...) Library, CINAHL, DARE and Current Controlled Trials were searched from January 1990 to June 2010 for articles in English. Search terms were reported. Reference lists of identified trials were searched. Study selection Randomised controlled trials (RCTs) of orlistat or sibutramine versus placebo in white and ethnic minority adult participants (aged 18 years and over) that evaluated changes in weight or body mass index (BMI) and at least one secondary outcome (waist circumference, fasting lipid

2012 DARE.

93. Cost-effectiveness of pharmacotherapy to reduce obesity

Study objective This study evaluated the cost-effectiveness of pharmaceutical interventions, versus standard care, for obesity in Australian adults aged 20 years or older. Interventions Pharmaceutical care consisted of either 15mg sibutramine, once daily, or 120mg of orlistat, thrice daily. Patients were allowed one 12-month course of treatment. This was compared with usual care, with no drug treatment. Location/setting Australia/primary care. Methods Analytical approach: The authors used a Markov (...) not take their medication. Weight regain data were from the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) trial for sibutramine and were assumed to be the same for orlistat. It was assumed that none of the weight loss was permanent. Monetary benefit and utility valuations: Health-related quality of life utilities were calculated, for the nine disease states, using disability-adjusted life-year (DALY) weights from an Australian study. Measure of benefit: The DALYs averted were

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

94. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

: sulfonylureas, meglitinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors, and weight-loss agents (orlistat and sibutramine). Outcomes of interest included glycated haemoglobin (HbA 1c ), hypoglycaemia, body weight, quality of life, long-term complications of diabetes, severe adverse events, and mortality. In included trials, the mean baseline glycated haemoglobin ranged from 6.6% to 10

2011 DARE.

95. Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

(such as orlistat, sibutramine, rimonabant, phenylpropanol or chlorpheniramine) that promote weight loss within 3 months before study; Take any medications that may affect test results, such as antibiotics, non-steroidal anti-inflammatory drugs, antacids containing aluminum or magnesium, diuretics, anticoagulants, central nervous system inhibitors, systemic corticosteroids, medications to slow down the gastrointestinal motility, and any drug that may possibly affect the absorption of the drug within 2 weeks

2017 Clinical Trials

96. Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

, and lithium) thioridazine, clozapine, Currently using or have used within three months prior to screening for this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine (either by prescription or as part of a clinical trial) Simultaneous participation in any other clinical trial of an investigational drug The receipt of any investigational product within four weeks prior to screening for this trial Herbal supplements or over-the-counter medications Diet attempts using herbal

2017 Clinical Trials

97. Treatment of Pediatric Obesity: An Umbrella Systematic Review. (PubMed)

circumference, BMI, and diastolic blood pressure (low quality of evidence). Pharmacological interventions reduced BMI (metformin, sibutramine, orlistat) and waist circumference (sibutramine, orlistat) and increased high-density lipoprotein cholesterol (sibutramine) but also raised systolic and diastolic blood pressure (sibutramine). Surgical interventions (laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy) resulted in the largest BMI reduction (moderate quality

Full Text available with Trip Pro

2017 The Journal of clinical endocrinology and metabolism

98. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.

]), new-onset diabetes (113[NS] vs. 390[425-778]), bleeding (∞ vs. 517[317-1153]), and infection (∞ vs. 253[164-463]) with niacin-laropiprant; psychiatric disorders (12[7-34] vs. 9[5-24]) with rimonabant; myocardial infarction (MI) [-1305 vs. 270[89-4362]) with rofecoxib; MI (-510 vs. NNTH ranging from 152[55-4003] to 568[344-1350]) with rosiglitazone; cardiovascular events (∞ vs. 245[129-1318]) with sibutramine; and liver injury (∞ vs. 5957[NS]) with ximelagatran.NNTH have potential of use

2017 Expert opinion on drug safety

99. Effect of Combined Morphine and Duloxetine on Chronic Pain

, lithium, linezolid, tramadol (Ultram), St. John's Wort, central nervous system (CNS) stimulants such as amphetamine, methylphenidate, methamphetamine, phentermine, diethylpropion, sibutramine, cocaine, or thioridazine. Subject has uncontrolled narrow-angle glaucoma. Subject has sensory deficits on arms or Raynaud's Syndrome. Subject has a pending litigation related to chronic pain condition. Subject is on methadone or suboxone treatment for addiction. Contacts and Locations Go to Information from

2017 Clinical Trials

100. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

or hypersensitivity to any of the ingredients in the test products. Cognitive impairment or any other reason to expect the patient would have difficulty complying with study protocol Excessive alcohol intake defined as greater than 3 units of alcohol per day. Use of weight loss drugs (e.g., lorcaserin [Belviq]; phentermine/topiramate [Qsymia], liraglutide [Saxenda], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanol-amine], or similar over-the-counter medications) within 3 months of the screening

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>